Get the Stockscreener App
32.30
1.89%
-0.575
Immunocore Holdings Plc Adr stock is traded at $32.30, with a volume of 65,769.
It is down -1.89% in the last 24 hours and down -11.15% over the past month.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
See More
Previous Close:
$32.88
Open:
$33.09
24h Volume:
65,769
Relative Volume:
0.17
Market Cap:
$1.62B
Revenue:
$357.71M
Net Income/Loss:
$-20.10M
P/E Ratio:
-81.60
EPS:
-0.3959
Net Cash Flow:
$28.67M
1W Performance:
+1.16%
1M Performance:
-11.15%
6M Performance:
+10.48%
1Y Performance:
-11.37%
1-Day Range:
$32.20
$33.27
1-Week Range:
$31.04
$33.80
52-Week Range:
$23.15
$39.33
Immunocore Holdings Plc Adr Stock (IMCR) Company Profile
Name
Immunocore Holdings Plc Adr
Sector
Industry
Phone
01235 5430281
Address
90 PARK DRIVE, OXFORDSHIRE
Compare IMCR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMCR
Immunocore Holdings Plc Adr
|
32.24 | 1.66B | 357.71M | -20.10M | 28.67M | -0.3959 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.32 | 100.71B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
576.58 | 61.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.26 | 58.84B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
665.24 | 40.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
325.03 | 38.20B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunocore Holdings Plc Adr Stock (IMCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-27-25 | Initiated | Deutsche Bank | Buy |
| Dec-13-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-11-24 | Downgrade | Mizuho | Outperform → Neutral |
| Oct-24-24 | Initiated | UBS | Sell |
| Oct-07-24 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-29-24 | Initiated | Leerink Partners | Outperform |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Nov-02-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-31-23 | Initiated | Robert W. Baird | Outperform |
| Sep-13-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-13-23 | Initiated | Needham | Buy |
| Aug-16-23 | Initiated | CapitalOne | Overweight |
| Jul-17-23 | Initiated | Canaccord Genuity | Hold |
| Mar-31-23 | Initiated | Mizuho | Buy |
| Mar-30-23 | Initiated | Guggenheim | Buy |
| Mar-24-23 | Initiated | Bryan Garnier | Buy |
| Dec-16-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-30-22 | Initiated | Barclays | Overweight |
| Sep-09-22 | Initiated | Morgan Stanley | Overweight |
| Sep-08-22 | Initiated | Ladenburg Thalmann | Buy |
| Aug-08-22 | Initiated | Cowen | Outperform |
| Aug-02-22 | Initiated | BTIG Research | Buy |
| Feb-08-22 | Initiated | H.C. Wainwright | Buy |
| Oct-20-21 | Initiated | Oppenheimer | Outperform |
| Mar-02-21 | Initiated | Goldman | Neutral |
| Mar-02-21 | Initiated | JP Morgan | Overweight |
| Mar-02-21 | Initiated | Jefferies | Buy |
View All
Immunocore Holdings Plc Adr Stock (IMCR) Latest News
Q3 Earnings Estimate for Immunocore Issued By HC Wainwright - Defense World
FY2027 EPS Estimates for Immunocore Boosted by HC Wainwright - Defense World
Immunocore’s SWOT analysis: stock outlook amid clinical milestones, market challenges - Investing.com
IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi - sharewise.com
PBYI's Q2 Earnings Beat Estimates, Nerlynx Sales Drive Revenues - sharewise.com
Nektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y - Yahoo Finance
Immunocore (IMCR) Q2 Revenue Jumps 30% - The Motley Fool
Compared to Estimates, Immunocore (IMCR) Q2 Earnings: A Look at Key Metrics - Yahoo Finance
Immunocore Holdings earnings missed by $0.02, revenue topped estimates - Investing.com South Africa
Perrigo Beats on Q2 Earnings & Sales, Stock Down on '25 Sales View Cut - Yahoo Finance
TGTX Down as Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line - sharewise.com
AXSM Q2 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y - The Globe and Mail
CORT's Q2 Earnings Top Mark, Revenues Lag, '25 View Cut, Stock Down - Yahoo Finance
Amarin's Q2 Earnings & Revenues Trump Estimates, Stock Rises - Barchart.com
Immunocore to Report Q2 2025 Financial Results on August 7, 2025 - AInvest
Analysts Set Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) PT at $58.89 - Defense World
Wall Street Analysts See a 72.34% Upside in Immunocore (IMCR): Can the Stock Really Move This High? - Yahoo Finance
The IMCR Stock Puzzle: Unraveling Immunocore Holdings plc ADR’s Fluctuating Performance - investchronicle.com
Can Mizuho Financial Group, Inc. ADR Bounce Back? 52-Week Performance and Analyst Predictions - investchronicle.com
Principal Financial Group Inc. Reduces Stock Holdings in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) - Defense World
Immunocore Holdings ADR Earns IBD Rating Upgrade - Investor's Business Daily
MBIO Soars on Orphan Drug Nod for Investigational Brain Cancer Therapy - sharewise.com
COGT Stock Soars on Phase III Systemic Mastocytosis Study Success - sharewise.com
5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment - Yahoo Finance
Biogen Begins Phase III Felzartamab Study for Third Kidney Disease - Yahoo Finance
Wall Street Analysts See an 114.35% Upside in Immunocore (IMCR): Can the Stock Really Move This High? - MSN
FDA Grants Label Expansion to AstraZeneca's Datroway in Lung Cancer - Yahoo Finance
FDA Extends INCY's Application for Opzelura Label Expansion - Yahoo Finance
Immunocore’s SWOT analysis: stock outlook amid pipeline progress, market challenges By Investing.com - Investing.com South Africa
Immunocore’s SWOT analysis: stock outlook amid pipeline progress, market challenges - Investing.com India
Brokers Set Expectations for Immunocore FY2026 Earnings - Defense World
GAMMA Investing LLC Boosts Stock Position in Immunocore Holdings plc (NASDAQ:IMCR) - Defense World
Immunocore at Jefferies Global Healthcare Conference: Strong Growth and Promising Trials - Investing.com India
TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises - Yahoo Finance
Wall Street Analysts Think Immunocore (IMCR) Could Surge 65.22%: Read This Before Placing a Bet - sharewise
Deutsche Bank sets $65 target on Immunocore stock, rates Buy - Investing.com
Deutsche Bank sets $65 target on Immunocore stock, rates Buy By Investing.com - Investing.com India
Immunocore’s SWOT analysis: biotech firm’s stock faces challenges amid growth - Investing.com India
Is it a Good Idea to Invest in Immunocore Stock Right Now? - MSN
Balance Sheet Dive: Hippo Holdings Inc (HIPO)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
Analyzing Ratios: Symbotic Inc (SYM)’s Financial Story Unveiled - DWinneX
New Strong Buy Stocks for May 8th - The Globe and Mail
Immunocore stock rises as Q1 results top estimates By Investing.com - Investing.com South Africa
Immunocore stock rises as Q1 results top estimates - Investing.com
Immunocore Holdings earnings beat by $0.49, revenue topped estimates - Investing.com
Compared to Estimates, Immunocore (IMCR) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down - Barchart.com
AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y - The Globe and Mail
Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates - Barchart.com
Immunocore Holdings Plc Adr Stock (IMCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.30%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):